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Gastric Cancer – Overview 
Gastric cancer was the most common and most lethal cancer in the world during most 
part of the last century. Despite a gradual decrease in its incidence, it is still the 
fifthmost common malignancy (6.8% of all cancers), after lung, breast, colo-rectum and 
prostate and the third leading cause of cancer death (8.8% of total) after lung and liver 
cancers. More than 70% of the cases occur in developing countries.1 
In Portugal, the scenario is similar. Despite a slow decrease in stomach cancer 
mortality, it still represents one of the most important oncological problems.2 According 
to IARC Cancer Base, gastric cancer is the fifth most incident cancer in Portugal (6.1% 
of all cancers) and the third most deadly (9.5% of total). These values surpass the ones 
of WHO Europe Region (4.3% and 6.5% respectively).1, 3 
More than 90% of gastric tumours are adenocarcinomas.4 According to Lauren’s 
classification, these can be further divided into two main histopathological entities: 
intestinal and diffuse types.5 They differ in epidemiologic, clinic, pathologic and 
molecular patterns.6 
Intestinal type gastric carcinoma is the most common subtype and it is preceded by a 
prolonged precancerous cascade, most frequently initiated by Helicobacter pylori, that 
is still not fully understood.6, 7 Morphologically, it forms glands that range from well 
differentiated to moderately differentiated tumours and it typically arises on a 
background of chronic atrophic gastritis with intestinal metaplasia.6 
Diffuse type gastric carcinoma is not preceded by well-defined precancerous lesions.7 It 
also shows an association with H. pylori but, unlike intestinal type, it develops without 
passing through the intermediate step of intestinal metaplasia.8, 9 It may occur in an 
hereditary context, but most frequently it is sporadic. In both cases, loss of expression 
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of the cellular adhesion protein E-cadherin results, morphologically, in poorly cohesive 
cells diffusely infiltrating the gastric wall with little or no gland formation.6 
Gastric Cancer – Carcinogenesis Pathways 
Nowadays, the most accepted model of gastric 
carcinogenesis of the intestinal type still has its 
foundations on Correa’s model. According to 
Correa, a decades-long, multistep and 
multifactorial cascade starting with chronic 
gastric inflammation, progressing to gland loss 
and their replacement by intestinal-type 
epithelium, followed by loss of cellular 
differentiation, leads ultimately to the 
development of invasive gastric adenocarcinoma 
(figure 1).7, 10-12 
Tsukashita et al. have suggested that the tumourigenesis of low-grade dysplasia 
particularly with an intestinal phenotype may be different from high-grade dysplasia and 
intramucosal carcinomas with gastric phenotype.13 Nishimura et al. tested this 
hypothesis and concluded that non-invasive low-grade neoplasms of the intestinal 
lineage progress to non-invasive high-grade neoplasms but rarely to intramucosal 
adenocarcinomas, whereas intramucosal adenocarcinomas of the gastric lineage 
largely arise de novo from the proper gastric mucosa and are partially derived from 
non-invasive high-grade neoplasms.14 
These two models are not necessarily mutually exclusive so, although gastric 
carcinogenesis is not fully understood, we can admit that adenoma-carcinoma 
sequence is responsible for a subset of gastric cancers and that the rest of them may 
arise de novo. 
Figure 1 - Correa's Carcinogenesis Model 
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Risk Factors and Determinants of Gastric Carcinogenesis 
In its gastric carcinogenesis model, Correa also proposed that both deleterious and 
protective factors could modulate the progression/regression of this cascade.10 
Helicobacter pylori is the most frequent cause of gastritis, being classified by IARC as a 
type I (definite) human carcinogen in 1994.15 Two proposed mechanisms to step in the 
carcinogenic cascade are the immune response elicited by H. pylori and the damage 
resulting from oxidative stress.16 The severity of inflammation varies both with the 
virulence of H. pylori strains, given by vacA and cagA genotypes, and with 
proinflammatory host genetic polymorphisms in the IL1β, IL1RN and TNFα genes.17-19 
Eradication with antibiotic treatment can reverse this initial inflammatory reaction but 
intestinal metaplasia reversibility is still a controversial issue.20 Furthermore, intestinal 
metaplasia arises in only 30% of infected individuals, from which only around 7% will 
develop gastric cancer,9, 21 so the presence of other genetic/environmental factors 
modulating progression towards cancer has to be considered. 
Other risk factors for the development of sporadic gastric cancer include salt and 
nitrous compounds of the diet and tobacco smoking. On the other side, fresh fruits and 
vegetables may play a protective role.22 
Pre-malignant conditions and lesions - metaplasia and dysplasia  
Multifocal atrophic gastritis and intestinal metaplasia confer a high risk for the 
development of gastric cancer, thus they are considered to be precancerous 
conditions. 23 
Intestinal metaplasia represents a phenotypic change from the normal epithelial cell of 
gastric mucosa to an intestinal phenotype. One of its classifications divides IM into 
complete or incomplete type, both characterized by the presence of intestinal markers 
such as the transcription factor CDX2 and the mucin MUC2. Complete intestinal 
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metaplasia displays goblet and absorptive cells and no expression of gastric mucins. 
Incomplete intestinal metaplasia displays goblet and columnar non-absorptive cells, in 
which gastric mucins (MUC5AC, and MUC6) are co-expressed with the intestinal 
markers.24 This classification has clinical relevance since incomplete intestinal 
metaplasia confers a higher risk of progression to gastric cancer.25 
Gastric dysplasia (also known as intraepithelial neoplasia or non-invasive neoplasia) 
represents the penultimate stage of the gastric carcinogenesis sequence. 
Histologically, it is defined by unequivocal neoplastic epithelium without evidence of 
tissue invasion, and is thus a direct neoplastic precancerous lesion.23 The term 
adenoma refers to a raised circumscribed dysplastic lesion protruding above the 
mucosal surface.26 
Observation of different degrees of cellular and architectural atypia allows classification 
into low and high grade dysplasia.27 Most patients harboring lesions classified as high 
grade dysplasia are at high risk for either synchronous invasive carcinoma or its rapid 
development.28, 29 
Dysplasia can also be classified, according to its phenotypical characteristics, into 
adenomatous/intestinal or foveolar/gastric.30 These morphological types can be 
confirmed by immunohistochemistry techniques. Intestinal type has positivity to MUC2, 
CD10 and CDX2 and gastric type has positivity to MUC5AC and MUC6, lack of CD10 
and low CDX2 expression. Those which show both gastric and intestinal phenotypes 
are classified as hybrid/mixed phenotype while those showing neither gastric nor 
intestinal markers are grouped as null type.6 
Although the literature on the clinical relevance of this morphological classification is 
limited, some clues have aroused. Park et al have showed that adenomatous type 
dysplasia is associated with IM showing a complete intestinal phenotype, while foveolar 
and hybrid dysplasias are closer to incomplete IM.31 Also, Tsukashita et al 
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demonstrated that the majority of low-grade dysplasia (81.8 %) expresses intestinal 
markers and generally expresses no gastric markers, whereas more than half of high-
grade dysplasia expresses gastric markers (72.2%).13, 31 
Molecular Pathology 
The research on the determinants of gastric cancer precursors has been less extensive 
than for the cancer endpoints and there are currently no immunohistochemical or 
molecular assays that can help stratify the risk of progression of gastric dysplastic 
lesions. 
The genetic and molecular abnormalities occurring during gastric carcinogenesis 
include chromosomal instability, CpG-island methylation and microsatellite instability 
(MSI).30 
Chromosomal instability refers to copy number variations and is the predominant type 
of genomic instability, being present in more than 60% of gastric cancers.32, 33 Loss of 
heterozygosity at the TP53 locus was demonstrated in 14% of a series of metaplastic 
lesions, in 22% of gastric dysplastic lesions and 30% to 50% of gastric carcinomas, 
consistent with their role in cancer progression.30 
Aberrant DNA hypermethylation occurs preferentially in CpG islands.33 Among gastric 
adenomas, it was described in genes involved in cell cycle regulation (p14, p16, 
COX2), signal transduction (APC), DNA repair (hMLH1 and MGMT) and invasion and 
metastasis (E-cadherin and TIMP3).30 RUNX3 is a recently recognized tumor 
suppressor gene for gastric cancer. An increase in the proportion of its promoter 
methylation along gastric carcinogenesis was described, with 16% in chronic atrophic 
gastritis, 37% in IM, 42% in gastric adenoma, 55% in dysplasia, and 75% in GC 
tissues, suggesting its importance at the later stages of gastric carcinogenesis.30, 33 
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MSI phenotype results from accumulating genomic mutations due to inactivation of the 
DNA mismatch repair pathway, through promoter hypermethylation and loss of 
expression of MHL1. MSI has been documented both in intestinal metaplasia and in 
dysplastic lesions (~20%) being therefore considered among the early molecular 
events in gastric carcinogenesis.32 
Based on gene expression profiling, three gastric tumor subtypes were identified. They 
were classified as proliferative, mesenchymal, and metabolic and they show differential 
sensitivities to chemotherapy agents.34 
Although molecular events underlying gastric carcinogenesis are not fully uncovered, it 
is becoming evident that the balance between gastric and intestinal differentiation has 
a significant impact, at least in the early steps of the gastric carcinogenesis cascade, 
with the most frequent pre-malignant condition resulting from a switch of gastric to an 
intestinal differentiation profile. 
CDX2 – An intestinal differentiation transcription factor 
CDX2 is a transcription factor member of the caudal-related homeobox gene family 
with an important role for intestinal epithelial development.35 In normal conditions, 
CDX2 is expressed in small intestinal and colonic epithelia, but not in gastric 
epithelium.36 However, in certain unfavourable conditions to the normal gastric mucosa 
environment – usually elicited by H. pylori infection – gastric epithelial cells may 
acquire ectopic expression of CDX2 and transdifferentiate into an intestinal phenotype 
– intestinal metaplasia.37-40 
The strength of these observations largely come from transgenic mouse models 
studies, in which CDX2 was under the control of promoters from different gastric-
specific genes (Foxa3 or H+/K+-ATPase b-subunit). Mutoh et al. and Silberg et al. 
reported that the ectopic expression of CDX2 in the gastric mucosa of transgenic mice 
alone was sufficient to induce a complete transformation of the gastric mucosal glands 
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to intestinal-like mucosa, confirming the crucial role of CDX2 in intestinal 
differentiation.37, 38 A posterior paper of Mutoh et al. also showed that long-term 
intestinal metaplasia of the CDX2 transgenic mice induced invasive gastric 
carcinoma.41 
Some degree of this CDX2 abnormal expression is maintained in the progression to 
gastric dysplasia and gastric cancers.39, 42 Although Kim et al demonstrated a positive 
correlation between CDX2 expression and the increasing grade of dysplasia and 
carcinoma,43 more recent papers described the opposite association, with CDX2 
expression progressively reduced in gastric dysplasia and cancer.42, 44, 45 Other authors 
reported a significantly decreased CDX2 expression in incomplete intestinal metaplasia 
compared with complete intestinal metaplasia,39, 44 and an inverse association between 
CDX2 expression in gastric cancer and the expression of gastric mucins MUC5AC and 
MUC6.42, 44 Also, CDX2-positive tumours have a better outcome than CDX2-negative 
tumours, with less invasiveness, fewer lymph node metastases and a higher 5-year 
survival.42, 45 Based on these findings, a tumour suppressor role was suggested for 
CDX2 in human gastric carcinogenesis,42, 45 similarly to colorectal cancer.46, 47 
SOX2 – A gastric differentiation transcription factor 
SOX proteins are important transcription factors with pleiotropic functions – stem and 
progenitor cell fate determination, cell differentiation, proliferation, reprogramming, 
tissue homeostasis and repair.48 They constitute a large family of genes – with 20 
different SOX genes identified until now49 – and they have in common the HMG domain 
similarity with Sry (sex-determining region Y).48 
In normal tissues, SOX2 is expressed in the foregut-derived organs such as pharynx, 
oesophagus and stomach, but not in hindgut-derived organs such as intestine, where 
the CDX1 and CDX2 proteins assume the responsibility of cell differentiation.50, 51 
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Several other tissues also have been shown to express SOX2, among them are 
trachea, lung, tongue, cervix, brain, skin and bone.48  
In normal stomach, SOX2 has a nuclear expression, mainly in the neck region of the 
gastric glands, both at the body and antrum regions. Starting with H. pylori stimuli,40 a 
progressive reduction of the expression of SOX2 from normal gastric mucosa to 
incomplete intestinal metaplasia, then to complete intestinal metaplasia51 and to 
adenocarcinoma,50, 52 has been demonstrated, along with an inverse increase of CDX2 
expression.51 This CDX2-SOX2 interplay was comprehensively demonstrated both with 
in vitro40, 53, 54 and with transgenic mouse models studies. Conditional knock-out of the 
CDX2 gene in mice showed increased SOX2 expression in the regions where CDX2 
expression was deficient, with a consequent shift from an intestinal to a 
gastric/esophageal differentiation.55, 56 The same was observed when ectopic 
expression of SOX2 was induced in the intestine.57 Also, it has been shown that SOX2 
up-regulates stomach-specific expression of pepsinogen A58 and MUC5AC genes.59 
Another finding is the higher SOX2 expression in adenocarcinomas expressing gastric 
mucins compared to adenocarcinomas expressing intestinal mucins.50, 60 For all these 
reasons, SOX2 is a highly suspected candidate for gastric differentiation.  
SOX2 expression has been positively associated with tumour grade and with worse 
prognosis in a variety of tumours.61 Concerning gastric adenocarcinoma, conflicting 
results were published. Matsuoka et al found a statistically significant correlation 
between SOX2-positive expression and depth of tumour invasion, lymph node 
metastasis and lymphatic invasion.62 On the other hand, Otsubo et al reported that 
SOX2 expression is frequently down-regulated in human gastric cancer, through 
aberrant DNA methylation, associating with a significantly shorter survival time. Also, 
they showed that SOX2 inhibits proliferation, induces cell-cycle arrest and apoptosis in 





This work aims to better characterize the balance of gastric vs. intestinal differentiation 
in the precancerous conditions and lesions of the gastric carcinogenesis cascade 
through a systematic description of SOX2 expression in the normal gastric mucosa, 
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Gastric cancer remains a major health concern worldwide. Intestinal metaplasia (IM), 
resulting from de novo expression of CDX2, and dysplasia are precursor lesions of 
gastric cancer associated with increased risk for cancer development. Multiple 
evidences suggest that SOX2 is a transcription factor with a role in gastric 
differentiation and its interplay with CDX2 may determine gastric carcinogenesis. Our 
aim was to assess SOX2 involvement in gastric premalignant conditions and lesions in 
an attempt to establish its relationship with CDX2 and with the differentiation 
reprogramming that characterizes gastric carcinogenesis. Characterization of gastric 
(SOX2, MUC5AC, MUC6) and intestinal (CDX2 and MUC2) markers in normal gastric 
mucosa, in 55 foci of IM and in 26 foci of dysplasia was performed by 
immunohistochemistry. In vitro models were used to study the putative cross-regulation 
between SOX2 and CDX2. SOX2 was expressed in the normal gastric mucosa, in the 
presumptive stem cell compartment, and was maintained in 7% of the complete and 
85% of the incomplete IM subtypes, the latter defined by MUC5AC expression. 12% of 
the dysplastic lesions expressed SOX2 and the association with MUC5AC was lost. 
Conversely, CDX2 was present in all IM and dysplastic lesions. Finally, SOX2 
negatively regulated CDX2 in a cell-type specific manner. In conclusion, SOX2 
associates with gastric differentiation and is lost in the progression to dysplasia, 
whereas CDX2 is de novo acquired in IM and maintained in dysplasia. This suggests 
that the balance between gastric and intestinal differentiation programs impacts on 
progression of the gastric carcinogenic cascade. 
 
 





Gastric cancer is the fourth most common malignancy and the second-leading 
cause of cancer-related deaths worldwide.1 The majority of gastric cancers is 
diagnosed late, and as such has a dismal prognosis, which is reflected by a 5-year 
survival rate of no more than 25%.2 Thus, the most promising strategies to control the 
disease are based on prevention and early diagnosis. Gastric cancer is usually initiated 
by an inflammatory process associated with infection by Helicobacter pylori, which may 
lead to multifocal atrophic gastritis, intestinal metaplasia (IM), dysplasia and finally 
cancer.3 IM is a switch from a gastric to an intestinal differentiation profile and is the 
most frequent premalignant condition of the stomach, appearing adjacent to more than 
80% of gastric cancers.4 It is an heterogeneous lesion with two subtypes, complete and 
incomplete, both characterized by the presence of intestinal markers such as the 
transcription factor CDX2 and the mucin MUC2. The complete IM subtype is defined by 
the absence of gastric differentiation markers, such as mucins MUC5AC and MUC6, 
whereas in the incomplete IM subtype there is concomitant expression of gastric and 
intestinal markers.5 This classification has clinical implications because the incomplete 
subtype is more frequently associated with gastric cancer and shows an increased risk 
for cancer progression.4,6  
CDX2 is a homeobox transcription factor critical for intestinal differentiation 7-
8and is a specific biomarker of the early steps of the gastric carcinogenic cascade, 
driving the onset of IM.9-10 The key role of CDX2 in the metaplastic transformation of 
the gastric mucosa was categorically demonstrated by two transgenic mouse models 
with ectopic expression of CDX2 in the gastric epithelium and subsequent development 
of IM with absorptive, goblet, and enteroendocrine cell types.11-12  
On the other hand, an increasing number of evidences support the involvement 
of the transcription factor SOX2 in gastric differentiation. SOX2 is a sex-determining 
region Y-box 2 gene, a member of the high mobility group (HMG) domain proteins that 
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is essential to maintain pluripotency in embryonic stem (ES) cells and also to 
reprogram fibroblasts into induced pluripotent (iPS) cells.13-14 More recently, it has also 
been identified as an adult stem cell marker in mice.15 Furthermore, modulating SOX2 
expression in mice demonstrated the importance of this protein in the differentiation of 
the esophageal epithelium and proper morphogenesis of the esophagus, trachea and 
lung.16-17 In the digestive tract, it was observed in chick and in mouse gut that SOX2 
and CDX2 expression are mutually exclusive.18-19 In vitro studies showed that SOX2 
negatively regulated the CDX2 promoter by hampering the action of other transcription 
factors in an intestinal context and that SOX2 downregulation led to CDX2 
overexpression in a gastric context.20-21 In accordance with these observations, we 
have demonstrated that SOX2 and CDX2 can be inversely regulated by the BMP 
pathway and Helicobacter pylori.22 Moreover, two mouse models with conditional CDX2 
loss of function, showed increased SOX2 expression in the regions where CDX2 was 
abrogated, with a consequent shift from an intestinal to a gastric/esophageal 
differentiation.23-24 The same was observed when forced expression of SOX2 was 
induced in the intestine,25-26suggesting that the interplay of these two transcription 
factors is critical for the balance between gastric and intestinal differentiation.  
Here, we sought to characterize SOX2 expression and the relationship with 
CDX2 in gastric cancer precursor lesions in an attempt to establish its involvement in 








MATERIAL AND METHODS 
Material 
Normal gastric mucosa was studied in 10 biopsies representative of the body (n 
= 5) and the antrum (n = 5) regions obtained from individuals with no gastric 
pathologies. IM (55 foci) and the adjacent gastric mucosa were studied in 11 surgical 
specimens obtained from patients with gastric carcinoma undergoing surgery at Centro 
Hospitalar S. João, Porto, Portugal. IM foci were classified into complete (n = 29) or 
incomplete (n = 26) type according to the pattern of mucin expression.5 Twenty-six foci 
of dysplasia were studied in 22 samples obtained by Endoscopic Submucosal 
Dissection (ESD) at the same hospital. Foci were considered distinct when they were 
separated by a stretch of gastric glands. The use of retrospective samples from which 




Paraffin–embedded specimens were subjected to immunohistochemistry for 
SOX2, CDX2, MUC5AC, MUC6 and MUC2 using the antibodies described in Table 1. 
Detection of CDX2, MUC5AC and MUC2 was performed by incubation with a biotin-
labeled rabbit anti-mouse secondary antibody (DAKO, 1:100) followed by incubation 
with an avidin/biotin detection system (Vectastain ABC kit, Vector Laboratories, 
Burlingame, CA, USA) and development with 3,3′-diaminobenzidine (DAB). Detection 
of SOX2 was done using the Dako REAL™ Envision™ Detection System 
Peroxidase/DAB+ (DAKO, Glostrup, Denmark) according to the manufacturer’s 
instructions.  
For double staining (SOX2/MUC5AC or SOX2/MUC6), immunohistochemistry 
was first performed for SOX2 using the Dako REAL™ Envision™ Detection System 
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Peroxidase/DAB+ (DAKO, Glostrup, Denmark) and immediately followed by 
immunohistochemistry for MUC5AC or MUC6 using the Envision™ G2 System/ AP 
(Permanent Red) (DAKO), according to the manufacturer’s instructions. Tissue 
counterstaining was performed using Mayer hematoxylin. Cases were considered 
positive when more than 5% of the cells were stained with each antibody. 
 
Cell Culture 
The human gastric carcinoma cell lines AGS (ATCC) and MKN45 (JCRB0254, 
The RIKEN Cell Bank) were maintained in RPMI1640-GlutaMAx (Gibco, Invitrogen), 
whereas the human colon carcinoma cell line Caco-2 (ATCC) was maintained in 
DMEM (Gibco, Invitrogen). Media were supplemented with 10% fetal bovine serum 
(Gibco, Invitrogen, Carlsbad, USA) and 1% antibiotics (10U/mL penicillin and 10μg/mL 
streptomycin) (Gibco, Invitrogen, Carlsbad, USA). Cells were maintained at 37ºC in a 
humidified 5% CO2 incubator. 
 
Transient transfection assays 
For AGS and MKN45, one day prior to transfection, cells (7.5x105) were 
seeded in 6-well plates. Transfection of the expression vector CMV/SOX2, (1ug/well) or 
the empty vector was carried out using Lipofectamine 2000 (Invitrogen) (1g DNA:1.5l 
lipofectamine ratio) in serum and antibiotic free OPTI-MEM (Gibco, Invitrogen). Cells 
were recovered 48h after transfection. Caco-2 cells were subjected to two consecutive 
rounds of transfection. Cells were seeded in 6-well plates and transfected either with 
the expression vector CMV/SOX2 or with the empty vector (1ug/well), as described 
above. The medium was changed and a second similar transfection was performed 72 
hours after platting. Cells were recovered 48h after the second transfection. 
22 
 
Protein Extraction and Western Blot 
Whole cell extracts were obtained by ressuspension of cell pellets in RIPA 
buffer (50mM TrisHCl pH 7.4, 150mM NaCl, 2mM EDTA, 1% NP-40, 0.1% SDS) in the 
presence of Complete protease inhibitors cocktail, (Roche, Indianopolis, USA) and 
quantification of total protein was determined by BCA protein assay (Pierce, Illinois, 
USA). Protein extracts were then subjected to standard SDS-PAGE, transferred to a 
nitrocellulose membrane (Amersham, GE Healthcare, UK) and blotted with primary 
antibodies (anti-CDX2,1:500, Biogenex; anti-SOX2, 1:4500, SIGMA; anti-β-actin, 
1:8000, SCBT) in 5% BSA (Sigma, St. Louis, USA) in TBS 0.01% Tween-20 (Sigma, 
St. Louis, USA). Peroxidase-conjugated secondary antibodies were used and 
developed with the ECL detection kit (Amersham, GE Healthcare, UK). Quantification 
of the western blots was performed using the Software Quantity One (BioRad, CA, 
USA). 
 
RNA extraction and Real-Time PCR 
Total RNA was extracted using TRI Reagent (Sigma, St. Louis, USA) and 
converted to cDNA using the SuperScript® II Reverse Transcriptase (Invitrogen, 
Carslbad, USA). CDX2 or 18S were amplified with SYBR Green (Applied Biosystems, 
Foster City, USA) in a fluorescence reader ABI Prism 7500. The levels of 18S were 
used for normalization and relative mRNA levels were calculated. Each experiment 
was carried out in triplicates at least twice; the results are expressed as means ± SD of 







Statistical analysis was performed using the StatView program (version 5.0). 
Distributions were compared by χ2 and Student’s t-test and significance was assumed 























SOX2 expression in the normal gastric mucosa 
We first characterized SOX2 expression in the normal gastric mucosa. For that 
purpose, we performed immunohistochemistry in 10 normal gastric mucosas and in 11 
gastric mucosas adjacent to IM. The pattern of expression was similar in all samples. 
SOX2 was mainly expressed in the nuclei of the cells in the neck region of the gastric 
glands, both at the body and antrum (Fig 1) and expression was progressively lost 
towards the surface. SOX2 expression is also less marked in the deep glands 
particularly in the body region (Fig 1).  
 
SOX2 expression in gastric premalignant lesions 
We next evaluated the expression pattern of SOX2 in gastric premalignant 
conditions and lesions: intestinal metaplasia and dysplasia. We performed 
immunohistochemistry in 26 foci of incomplete IM and 29 foci of complete IM, from a 
total of 21 cases. Complete and incomplete IM were defined, as previously described,5 
by the expression pattern of gastric mucins, with the complete type characterized by 
the absence of gastric mucins MUC5AC and MUC6 whereas the incomplete type 
expresses at least one of these mucins. SOX2 exhibited a distinct expression pattern 
according to the IM subtype, being expressed in 85% (22/26) of the incomplete IM foci 
and in 7% (2/29) of the complete IM foci (Table 2). Double immunostainings showed 
co-expression of SOX2 and MUC5AC in incomplete IM (Fig 2) and absence of both 
proteins in complete IM (Fig 2). MUC2 and CDX2 were expressed in all IM foci, as 




We next evaluated the expression pattern of SOX2 in 26 foci of dysplasia: low 
grade dysplasia (LGD) – 20 foci; high grade dysplasia – 6 foci. SOX2 was expressed in 
12% of the foci (3/26), all of low grade dysplasia (Table 3). Fig 3 shows dysplastic 
glands with SOX2 expression adjacent to negative ones. To further assess the 
differentiation characteristics of these dysplastic lesions we studied CDX2, MUC2, 
MUC5AC and MUC6 expression. The results are displayed in Table 3 and showed that 
all dysplastic foci expressed CDX2, 46% (12/26) expressed MUC2, 58% (15/26) 
expressed MUC5AC and 68%(17/25) expressed MUC6. Moreover, CDX2 expression 
was uniform throughout the lesions, similarly to IM, whereas expression of all mucins 
was scattered and heterogeneous (Fig 3). 
 
SOX2 and CDX2 cross-regulation 
Different studies with mice models suggest that CDX2 negatively regulates 
SOX2 and also the reverse.20-21,25-26 In order to determine if there is a direct cross-
regulatory mechanism between SOX2 and CDX2, which could be relevant in the onset 
of IM, we transiently transfected two gastric carcinoma cell lines (AGS and MKN45) 
and one colonic carcinoma cell line (Caco-2) with a CMV/SOX2 vector and the gastric 
carcinoma cell lines with a CMV/CDX2 expression vector (this experiment was only 
performed in the gastric cell lines since Caco-2 expresses CDX2 at high levels). The 
results obtained showed that in Caco-2 cells, increased SOX2 levels led to a 
decreased CDX2 expression both at the mRNA and the protein level (Fig 4) whereas in 







We have shown that SOX2 is consistently expressed in the normal gastric 
mucosa, mostly in the neck region, and in incomplete intestinal metaplasia (IM) 
conceivably explaining the maintenance of a gastric differentiation program in these 
cells. 
Gastric carcinogenesis is complex and so far largely elusive at the molecular 
level. However, understanding this process is key in order to design more effective 
screening and surveillance approaches or even revert preneoplastic lesions. One of the 
major pathways unfolds in a background of chronic atrophic gastritis and is associated 
with reprogramming of differentiation leading to IM. It is consensual that IM is an 
heterogeneous lesion, though different classification criteria have been proposed 
throughout the years, either based on morphological features or on mucin expression 
profiles. The mucin expression profile can be determined by classical histochemical 
methods using the periodic acid-Schiff, Alcian blue, and high iron diamine staining,28 or 
using immunohistochemistry,5 which was the approach applied in this study. 
Notwithstanding, all the methods lead to the classification of IM into complete and 
incomplete subtypes, based on loss or persistence of gastric differentiation together 
with acquisition of the intestinal one as currently accepted by most authors. 29 
Moreover, incomplete IM, regardless of the classification method used, is consistently 
more frequently associated with progression to cancer.4,6 The involvement of the 
transcription factor CDX2 in the transformation process leading to both types of IM is 
undisputable and now an explanation for the gastric phenotype observed in incomplete 
IM is suggested by the differential expression of SOX2.  
Our results clarified the profile of SOX2 expression, both in normal stomach and 
in gastric lesions, reinforcing its relationship with gastric differentiation.30-31 We show, 
for the first time, that SOX2 localizes predominantly to the neck region of the normal 
gastric epithelium, which is the proliferative compartment of the mucosa and the 
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expected location of gastric stem cells.32 This observation complies with a role of this 
transcription factor in the maintenance of the adult gastric epithelium, previously 
observed in mice15 and is in accordance with observations that SOX2 regulates 
MUC5AC and pepsinogen A, both of which are gastric differentiation markers.33-34 
Here, we also show that SOX2 is able to repress CDX2 expression, which might 
be one of the molecular mechanisms involved in maintaining normal gastric 
differentiation and, when deregulated, in IM onset. In fact, it was shown in other models 
that SOX2 downregulates CDX2 expression via SOX21.25 This adds to other molecular 
mechanisms that might also be involved in IM, namely the BMP pathway, that is 
overexpressed in gastric IM, upregulates CDX2 and downregulates SOX2 in a gastric 
carcinoma cell line.22,35 The potential interactions and or synergies of these different 
molecular mechanisms need further clarification. 
Finally, we disclosed the expression pattern of SOX2 and CDX2 in gastric 
dysplasia. We showed that the majority of dysplastic lesions do not express SOX2 
whereas all of them express CDX2, which is in accordance with Rugge et al.36 These 
two events suggest that the progression from normal gastric mucosa to dysplasia 
occurs concomitantly with gain of intestinal and loss of gastric differentiation, favoring 
the theory that dysplasia arises from metaplasia. This complies with the conclusions of 
Gutierrez-Gonzalez et al. showing that IM and dysplasia share genetic mutations in 
tumor suppressor genes, either APC or p53, in three cases.37 Likewise, Barrett’s 
esophagus which is a very similar lesion to gastric IM, is considered a bona fide 
preneoplastic lesion where dysplasia ensues. Mutations in p53 or p16 were identified in 
Barrett’s esophagus and dysplasia, further supporting the morphological evidences.38 
Our results thus reinforce the link between IM and dysplasia in the gastric setting, 
based on the expression of SOX2 and CDX2. This observation, strengthened by 
previous findings that IM is a lesion difficult to revert or even a “point of no return”39 has 
clinically relevant implications namely regarding surveillance of patients with IM, which 
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is in line with recent epidemiological data.40 Curiously, SOX2 and CDX2 no longer 
associate with mucin expression in dysplastic foci. A possible interpretation could be 
that these genes become subjected to regulatory mechanisms associated with the 
transformation process.  
In this study we have demonstrated that SOX2 is expressed in the normal 
stomach and is maintained in incomplete IM explaining the gastric differentiation still 
observed in these lesions. Given that SOX2 expression is lost both in dysplasia and in 
the complete IM subtype, we hypothesize that incomplete IM is a transient state that 
precedes the onset of both premalignant lesions (Fig 5). In conclusion, the balance 
between gastric and intestinal differentiation has a significant impact at least in the 
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Figure 1- SOX2 expression in the normal gastric mucosa. A and C) H&E staining of 
gastric mucosa from incisura and antrum, respectively. (B and D) Immunodetection of 
SOX2 (brown) in the same regions of the gastric mucosa. 
 
Figure 2- SOX2 expression in intestinal metaplasia. H&E staining showing gastric 
mucosa with intestinal metaplasia (A). Double immunodetection of SOX2 (brown) and 
MUC5AC (red) showing the presence of complete (MUC5AC negative) and incomplete 
(MUC5AC positive) IM glands (B and inset).  
 
Figure 3- Expression of SOX2, CDX2, MUC5AC and MUC2 in gastric dysplasia. 
Dysplastic foci were immunostained for the gastric differentiation markers SOX2 (A and 
inset) and MUC5AC (D) and intestinal differentiation markers CDX2 (B) and MUC2 (D). 
In (A) arrowhead indicates dysplastic glands with SOX2 expression whereas the arrow 
indicates dysplastic glands without SOX2 expression. In (D) arrow indicates IM with 
homogeneous MUC2 expression as opposed to dysplasia where expression is 
scattered (arrowhead). 
 
Figure 4- SOX2 overexpression in Caco-2 cells. Caco-2 colonic cell line was transiently 
transfected either with an empty vector or a SOX2 expression vector. The effect of 
SOX2 expression on CDX2 protein and RNA levels was assessed by western blotting 
(right) and qRT-PCR (left), respectively. 
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In spite of our well-established understanding of the phenotypic natural history 
occurring in the shift from native epithelia to invasive intestinal-type carcinoma in the 
gastric mucosa, the molecular typing of the precancerous changes in gastric mucosa 
remains elusive.1 It is, however, becoming evident that the balance between gastric 
and intestinal differentiation may play a significant role, at least in the early steps of the 
carcinogenesis cascade. It has been shown that the transcription factors SOX2 and 
CDX2 are stomach and intestine-specific, respectively,2, 3 thus they may provide a 
useful tool to analyse this cascade. 
In this study, we performed a systematic characterization of SOX2 expression along 
the precancerous cascade using immunohistochemistry in a series of 10 cases of 
normal gastric mucosa obtained from patients with no gastric pathology, 55 foci of IM 
adjacent to gastric carcinomas or to dysplasia, and 26 foci of dysplasia. We also used 
in vitro models to determine if there is a cross-regulation between SOX2 and CDX2. 
Contrary to other authors, we have used an anti-SOX2 monoclonal antibody, raising 
the confidence level on the immunohistochemistry method and results. Also, the double 
immunostaining technique provides valuable information about the co-localization of 
the different markers. The small number of cases included might be pointed out as a 
limitation of the study. 
We have shown that SOX2 expression is localized especially in the neck region of 
normal gastric glands, which is similar to other authors’ findings.4 This is the 
proliferative compartment of the mucosa and the expected location of gastric stem 
cells,5, 6 which is consistent with previous papers describing SOX2 role in stem cell 
maintenance.7 However, the number of positive cells is greater than expected if SOX2 
was only expressed in stem and progenitor cells, which suggests that this transcription 
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factor is not only required to switch on a gastric differentiation program, but also to 
maintain it in terminally differentiated cells. 
In intestinal metaplasia (IM), SOX2 is expressed in cases that maintain a gastric 
phenotype, characterized by the presence of the MUC5AC mucin and defining the 
incomplete IM subtype. By contrast, in complete IM, SOX2 expression is lost 
concomitantly with loss of MUC5AC. These two aspects are especially evident with the 
double SOX2/MUC5AC immunostaining. Previous studies have also described SOX2 
expression in human IM and, despite a different IM classification, the co-expression of 
SOX2 with MUC5AC or the absence of both SOX2 and MUC5AC was also observed.4, 
8 These observations are according with the expected role of SOX2 in the maintenance 
of gastric differentiation in incomplete type IM. 
The expression pattern of SOX2 in gastric dysplasia was so far unknown. We showed 
for the first time that the majority of dysplastic lesions do not express SOX2 (3 out of 
26) whereas all of them express CDX2. The positive cases were all low-grade 
dysplasias. One would be tempted to relate this finding with the previous reports of 
SOX2 possible tumour suppressor role,9 but the series of cases is short and it would be 
a risky shot. Despite our expectation of finding a relation between SOX2 and MUC5AC 
expression in dysplasia, we could not find such association nor with CDX2 expression 
in this lesion. 
Although gastric carcinogenesis still is a mind-breaking issue, it is recognized that one 
of its major pathways develops in an H. pylori-induced background of chronic atrophic 
gastritis and is associated with reprogramming of differentiation leading to IM. CDX2 is 
documented as being a reliable responsible for this intestinal shift, leading to both 
types of IM. The differential expression of SOX2 in IM subtypes brought out the 
rationale for the maintenance of gastric differentiation in incomplete type IM.  
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While CDX2 expression is maintained in the progression to gastric dysplasia, SOX2 
expression is substantially lost. These two events suggest that the progression from 
normal gastric mucosa to dysplasia occurs concomitantly with gain of intestinal and 
loss of gastric differentiation.  
The regulatory mechanisms underlying CDX2 activation and SOX2 downregulation in 
the gastric setting are closer to be understood. A previous report of this group has 
shown that the BMP pathway, which is overexpressed in gastric IM, upregulates CDX2 
and downregulates SOX2 in a gastric carcinoma cell line.10, 11 Furthermore, conditional 
knock-out of the CDX2 gene in mice intestines’ showed increased SOX2 expression, 
with a consequent shift from an intestinal to a gastric/esophageal differentiation.12, 13 
The same was observed when ectopic expression of SOX2 was induced in the 
intestine.14 These observations point to a mutual negative regulation of SOX2 and 
CDX2. In this study, we could not confirm the regulation of SOX2 by CDX2 by simply 
transfecting cell lines with CDX2, which suggests that co-factors or mediators are 
required for this process. We could though confirm SOX2 ability to negatively regulate 
CDX2 expression in one cell line.  
One possible interpretation of our results would be that upon adverse events, the 
normal gastric mucosa evolves to a transient state of incomplete IM induced by CDX2. 
From this point, both SOX2 expression and gastric differentiation are lost, leading to 
complete IM with low evidence for further carcinogenic evolution. Otherwise, for 
unknown reasons, the transient incomplete IM expressing both transcription factors 
creates an unstable setting, prone to acquire genetic alterations in oncogenes or 
tumour suppressor genes that induces evolution to dysplasia, while maintaining the 
progressive loss of SOX2. This is also observed in gastric adenocarcinoma.9, 15 
In summary, SOX2 is expressed in the normal stomach and is maintained in 
incomplete IM explaining the maintenance of a gastric differentiation program in these 
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lesions. SOX2 expression is lost in the dysplastic lesions and in the complete IM 
subtype, so we hypothesize that incomplete IM may precede the onset of them both. 
The balance between gastric and intestinal differentiation has a significant impact in 
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